Brief: Armata And Innoviva Will Invest $25 Mln For Armata's Bacteriophage Development Programs
28/01/2020 12:30
Jan 28 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS AND INNOVIVA ANNOUNCE $25 MILLION
STRATEGIC INVESTMENT TO SUPPORT ADVANCEMENT OF ARMATA'S
BACTERIOPHAGE DEVELOPMENT PROGRAMS
* ARMATA PHARMACEUTICALS INC - INNOVIVA WILL PURCHASE
APPROXIMATELY 8.7 MILLION NEWLY ISSUED SHARES OF ARMATA'S COMMON
STOCK, AT A PRICE OF $2.87 PER SHARE
* ARMATA PHARMACEUTICALS INC - STOCK PURCHASES ARE EXPECTED
TO
OCCUR IN TWO TRANCHES
Source text for Eikon: ID:nPn7PFDHSa
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles